Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218075 | 0.91 | GSK3B (0.78) | GSK3BFLT3 | |
| SCHEMBL3208244 | 0.89 | GSK3B (1.00) | GSK3B | |
| Hydrochloric Acid SCHEMBL3218917 | 0.88 | GSK3B (0.98) | GSK3B | |
| SCHEMBL16321074 | 0.84 | GSK3B (0.75) | GSK3BFLT3ACHE | |
| SCHEMBL30068530 | 0.82 | RAB9A (0.61) | GSK3BCCNA2CDK2FLT3CCNA1 | |
| SCHEMBL5433264 | 0.82 | RAB9A (0.61) | GSK3BCCNA2CDK2FLT3CCNA1 | |
| SCHEMBL6957369 | 0.81 | GSK3B (0.70) | GSK3B | |
| SCHEMBL6952214 | 0.80 | GSK3B (0.62) | GSK3B | |
| SCHEMBL18838254 | 0.80 | GSK3B (0.59) | GSK3B | |
| SCHEMBL19101740 | 0.79 | GSK3B (0.68) | GSK3BCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594859-B1 | INDAZOLAMIDES WITH ANALGESIC ACTIVITY | ACRAF (IT) | 2010-06-23 | — | — | EP | claimed |
| US-7632849-B2 | N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)- 1-(1-methylethyl)-1H-indazole-3-carboxamide; antiarthritic agents; rheumatic diseases; osteoarthritis; fibromyaleia;anticarcinogenic agents, pain; neuropathic pain; immunoincompetance; trauma; antiischemic agents; multiple sclerosis | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-12-15 | — | — | US | claimed |
| US-20060052417-A1 | Indazolamides with analgesic activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052417-A1 | Indazolamides with analgesic activity | P2RX7, P2RX3, P2RX1 | GSK3B 2866/4885CCNA2 2526/4885CDK2 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.